08 February 2024
08 February 2024
A decision on the US Food and Drug Administration (FDA) approval for the combination regimen is anticipated by 8 October 2024.
Veru’s Ostarine has previously been investigated in five clinical studies in patients with muscle wastage caused by advanced cancer.
Redx is eligible to receive $880m from Jazz for potential cancer treatments.
The deal comprises contingent value rights that could see additional payments of $90m.
Traditional and next-generation antibiotics have proven incapable of alleviating the long-term threat of antimicrobial resistance (AMR).
BridgeBio is eligible to receive $100m in upfront payment from Kyowa Kirin.
The acquisition, which also includes Phase II asset AL101, closes gap to SpringWorks’ FDA-approved Ogsiveo.
Stalicla closes a successful Series B financing round and sets sights on Series C as interest stirs for central nervous system (CNS) disorder deals.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
